Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-104 for Crohn’s Disease and RHB-204 for NTM Infections
The new patent expands the robust patent portfolio covering RHB-104 and RHB-204   RedHill plans to initiate a pivotal Phase 3 study with RHB-204 for the treatment of pulmonary nontuberculous mycobacteria (NTM) infections in the second half of 2019   RedHill plans to meet with the FDA in the second ...
View HTML
Toggle Summary RedHill Biopharma Appoints Dr. June Almenoff as Chief Scientific Officer
TEL-AVIV, Israel and RALEIGH, N.C. , May 28, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced the appointment of Dr. ...
View HTML
Toggle Summary RedHill Biopharma to Present at 2019 BIO International Convention
TEL-AVIV, Israel and RALEIGH, N.C. , May 23, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today announced that Mr. ...
View HTML
Toggle Summary RedHill Biopharma Expands Commercial Management Team Ahead of Planned Talicia® Launch
Rob Jackson joins as Vice President of Marketing Robert J. Gilkin, Jr. joins as Vice President of Market Access Steven Thomasian to join as Vice President of Supply Chain TEL-AVIV, Israel and RALEIGH, N.C. , May 21, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. ...
View HTML
Toggle Summary RedHill Biopharma Reports First Quarter 2019 Financial Results and Operational Highlights
Key Highlights and Upcoming Milestones: NDA submitted to the FDA for Talicia ® for H. pylori infection, with potential U.S. commercial launch in Q4/2019, assuming FDA approval FDA meeting planned for H2/2019 to discuss design of confirmatory Phase 3 study and path to potential approval for RHB-104 ...
View HTML
Toggle Summary RedHill Biopharma Submits New Drug Application for Talicia® for H. pylori Infection
The NDA follows a recent positive pre-NDA meeting with the FDA   The NDA for Talicia ® is eligible for six-month priority review   Talicia ® is eligible for a total of eight years of U.S. market exclusivity, in addition to patent protection until at least 2034   RedHill continues to strengthen its ...
View HTML
Toggle Summary RedHill Biopharma to Host First Quarter 2019 Financial Results Conference Call on May 7, 2019
TEL-AVIV, Israel and RALEIGH, N.C. , April 30, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. ( Nasdaq : RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced that it will report ...
View HTML
Toggle Summary RedHill Biopharma to Present at Three Conferences in April
TEL-AVIV, Israel and RALEIGH, N.C. , April 04, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal diseases, today announced that the Company will ...
View HTML
Toggle Summary RedHill Biopharma to Present at the BIO-Europe Spring 2019 Conference
TEL-AVIV, Israel and RALEIGH, N.C. , March 18, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today announced that Mr. ...
View HTML
Toggle Summary RedHill Biopharma to Present at the 31st Annual ROTH Conference
TEL-AVIV, Israel and RALEIGH, N.C. , March 11, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ( Tel-Aviv Stock Exchange : RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today announced that Mr. ...
View HTML